{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Beyond TNF Inhibitors for IBD: New Safety and Efficacy Data Move Adhesion Factor Inhibitors Forward - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"U6obhTNRKq\"><a href=\"https:\/\/themedicalxchange.com\/en\/2013\/11\/06\/united-european-gastroenterology-week-uegw-2013\/\">Beyond TNF Inhibitors for IBD: New Safety and Efficacy Data Move Adhesion Factor Inhibitors Forward<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2013\/11\/06\/united-european-gastroenterology-week-uegw-2013\/embed\/#?secret=U6obhTNRKq\" width=\"600\" height=\"338\" title=\"&#8220;Beyond TNF Inhibitors for IBD: New Safety and Efficacy Data Move Adhesion Factor Inhibitors Forward&#8221; &#8212; The Medical Xchange\" data-secret=\"U6obhTNRKq\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2013\/11\/2342_UEGW_Table_1_EN.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Berlin \u2013 New biologics are poised to expand treatment options for inflammatory bowel disease (IBD). Although only one agent for which new data were presented at the 2013 United European Gastroenterology Week (UEGW) has demonstrated efficacy and safety in extensive clinical testing, several in clinical trials show promise. Together, the data generated by these agents demonstrate that mediators of inflammation other than tumor necrosis factor (TNF) provide effective targets for therapy in IBD. The relative anti-inflammatory effect provided by inhibition of alternative molecular targets may or may not exceed that of TNF inhibitors, but the major advantage of new biologics may be more localized activity in the gut, reducing risk of systemic adverse events."}